Department of Women's and Children's Health, "Agostino Gemelli" Foundation University Hospital, Rome, Italy.
Department of Women's and Children's Health, Catholic University of the Sacred Heart, Rome, Italy.
J Minim Invasive Gynecol. 2018 Jul-Aug;25(5):774-775. doi: 10.1016/j.jmig.2017.10.034. Epub 2017 Nov 8.
To demonstrate management of a rare case of an isolated intraparenchymal splenic metastasis of endometrial cancer with robotic-assisted surgery.
Case report (Canadian Task Force Classification III).
A 55-year-old patient with a history of endometrial cancer was found to have a splenic lesion on a follow-up examination. She underwent surgical staging, involving total hysterectomy, bilateral salpingo-oopherectomy, pelvic lymphadenectomy, and peritoneal washing, in 2014, and the final pathological findings showed an endometrioid endometrial adenocarcinoma, International Federation of Gynecology and Obstetrics stage IB G2. Multidisciplinary counseling was provided, and the patient opted for strict medical surveillance. At 20 months after the primary treatment, the patient experienced a vaginal cuff recurrence and refused radiation therapy. She instead underwent robotic surgery, followed by 6 cycles of carboplatin 6 AUC and paclitaxel 175 mg/m. Seventeen months later, a positron emission tomography/computed tomography scan revealed a 3-cm intraparenchymal lesion of the spleen, and robotic splenectomy was scheduled. The Institutional Review Board approved this study.
The operative time was 90 minutes, and blood loss was <50 mL. The operation was performed successfully, with no intraoperative and postoperative complications. Histopathological analysis showed a 3-cm intraparenchymal splenic lesion. The patient was discharged on day +2, and 46 days later started adjuvant chemotherapy based on carboplatin 6 AUC and doxorubicin (Caelyx) 30 mg/m. At a 2-month follow-up, the patient was disease-free and in good general condition.
This case demonstrates the successful robotic management of recurrent endometrial cancer.
展示机器人辅助手术治疗子宫内膜癌孤立性脾内转移的罕见病例的处理方法。
病例报告(加拿大任务组分类 III 级)。
一名 55 岁的子宫内膜癌病史患者在随访检查中发现脾脏病变。她于 2014 年接受了手术分期,包括全子宫切除术、双侧输卵管卵巢切除术、盆腔淋巴结切除术和腹腔冲洗术,最终病理结果显示为子宫内膜样子宫内膜腺癌,国际妇产科联合会(FIGO)IB G2 期。提供了多学科咨询,患者选择了严格的医学监测。在初次治疗后 20 个月,患者出现阴道残端复发,拒绝接受放疗。相反,她接受了机器人手术,随后接受了 6 个周期的卡铂 6 AUC 和紫杉醇 175mg/m。17 个月后,正电子发射断层扫描/计算机断层扫描显示脾脏 3cm 实质内病变,计划进行机器人脾切除术。机构审查委员会批准了这项研究。
手术时间为 90 分钟,失血量<50ml。手术成功完成,无术中及术后并发症。组织病理学分析显示脾脏 3cm 实质内病变。患者于术后第 2 天出院,46 天后开始基于卡铂 6 AUC 和多柔比星(Caelyx)30mg/m 的辅助化疗。在 2 个月的随访中,患者无疾病且一般状况良好。
本病例成功地展示了机器人治疗复发性子宫内膜癌的方法。